LLY Puts Dominate: Why the $1,130 Support Test Signals a Strategic Dip Buy

• Eli Lilly (LLY) is trading at $1,129.35, testing critical support near the lower Bollinger Band.
• Heavy put open interest at $690–$720 suggests institutional hedging, not panic selling.
• Strong Q2 earnings and a $750M manufacturing expansion provide a fundamental floor for the stock.
• Technical indicators point to a short-term pullback within a long-term bullish trend.

The market is currently holding its breath. Eli Lilly has just pulled back from its recent highs, and while the long-term story remains incredibly strong, the short-term mechanics are screaming caution. The options market isn't betting on a crash; it’s betting on a pause. With the stock dipping below key moving averages, traders are asking: Is this a trend reversal or just a breather? The data suggests the latter. We’re seeing a classic accumulation dip, where smart money uses volatility to hedge downside risk while preparing to buy the next leg up.

Where the Money is Hiding

Let’s look at the options chain, because that’s where the real truth often hides. The Put/Call ratio for open interest is sitting at 1.27. On the surface, that looks bearish. But context is everything. If you look at the specific strikes, the heavy put volume isn’t at current prices. It’s clustered way down at $690, $720, and $740 for this Friday’s expiration ($20260807P690, $20260807P720). These are far out-of-the-money. Institutional investors are buying these as insurance policies, not as directional bets. They are protecting gains, not fleeing the ship.

On the call side, the open interest is spread across higher strikes like $1,220 and $1,300 ($20260807C1220, $20260807C1300). This indicates that while there’s hesitation now, the expectation is still for an eventual breakout above $1,200. There were no significant block trades today, which is actually a good sign. It means there’s no hidden whale dumping shares in the dark. The selling pressure you see is likely retail profit-taking or algorithmic rebalancing, which tends to be less persistent.

Fundamentals Back the Floor

The news flow this week has been overwhelmingly positive, and it directly contradicts the short-term bearish sentiment in the price action. Eli Lilly just announced a $750 million investment to expand U.S. manufacturing capacity for its diabetes and obesity drugs. This is huge. It addresses the biggest complaint investors have had: supply constraints. If you can’t sell the product, you can’t grow. By partnering with Resilience to create 400 new jobs and boost output, Lilly is removing a major bottleneck.

Furthermore, the completion of the late-stage trial for Retatrutide is a game-changer. This triple agonist has shown superior efficacy in weight loss compared to existing GLP-1 therapies. It’s the next wave of growth, and it’s coming. Analysts have responded in kind, with Barclays raising its target to $1,400 and RBC to $1,500. The legal noise from Novo Nordisk is just background static—a distraction that rarely impacts the long-term valuation of a company with this much cash flow and pipeline depth.

Actionable Trading Opportunities

So, how do we trade this? The technicals show a short-term bearish trend but a long-term bullish one. The RSI is at 43.6, which is neutral-to-weak but not oversold. The stock is currently hovering right at the lower Bollinger Band ($1,131.80). This is a key level.

For stock traders, the opportunity lies in buying the dip. Consider entering a long position near $1,128–$1,130. If the stock holds this support, the next resistance is the 30-day moving average around $1,176. A stop-loss should be placed just below the recent intraday low of $1,128.68 to protect against a breakdown.

For options traders, the risk/reward is better skewed towards calls if you’re willing to hold through the week. Given the heavy put hedging at lower levels, a downside crash is unlikely. However, buying calls this Friday might be too expensive due to theta decay. Instead, look at next Friday’s expirations ($20260814).

• Bullish Play: Buy the LLY20260814C1150 call. This strike is slightly out-of-the-money, offering leverage if the stock bounces off support. The premium is likely lower than the weekly options, giving you more time for the thesis to play out.
• Conservative Play: Buy the LLY20260807C1130 call if you believe the support will hold today. This is a tighter play, capitalizing on a quick rebound toward the middle Bollinger Band.

Volatility on the Horizon

We are standing at a crossroads. The short-term momentum is down, but the fundamental engine is roaring. The heavy put open interest at lower strikes acts as a spring, likely to push the price back up once support is tested and held. Don’t let the red today scare you off. This is a healthy correction in a powerful uptrend. Keep your stops tight, watch the $1,130 level closely, and be ready to step in if the market shows signs of stabilization. The next move is likely up, but it requires patience to let the dust settle.